‘First-in-Man’ Implant of Regenerative Cell Therapy

‘First-in-Man’ Implant of Regenerative Cell Therapy In Parkinson’s Disease

20 September 2013: Sydney, Australia & Auckland, New Zealand – Living Cell Technologies (LCT) Limited today announced that the first patient has been successfully implanted in the Phase I clinical trial of the regenerative cell therapy NTCELL® – a potential treatment for Parkinson’s disease.

The pioneering brain surgery was conducted yesterday at Auckland City Hospital and the patient has so far recovered well, although the full impact of the surgical procedure will not be known for several days. The patient and family have requested privacy and no contact with the media.

The Phase I clinical trial is an open label investigation of the safety and clinical effect of NTCELL in four people who have been diagnosed with Parkinson’s disease for at least four years. The first patient will now be monitored for two months to confirm no serious adverse safety events. At that time, the independent data safety monitoring board (DSMB) will consider the safety data and advise if the implants for the remaining three patients can proceed.

The trial Principal Investigator is Dr Barry Snow (MBChB, FRACP, FRCPC), an internationally recognised clinician and researcher in Parkinson’s disease who leads the Auckland Movement Disorders Clinic at the Auckland District Health Board. “The team is pleased with how well the patient tolerated the procedure itself,” says Dr Snow. “The surgery is relatively straightforward in neurosurgery terms, and we have taken full advantage of well-established techniques, which lower the clinical risk. The patient will now be monitored closely by the team over the next two months.”

Dr Andrea Grant, CEO and Managing Director of LCT says: “This is a significant milestone for the team. It has taken a great deal of hard work, clinical and scientific endeavour to get to this. But we do temper our excitement with realism – this first trial needs to demonstrate the treatment is safe before we can start thinking about the extent of clinical benefit that patients might gain.”

In the clinical trial, NTCELL is injected under guidance by neuroimaging into the affected area of the human brain where substantial death of neurons and other cells has occurred. The cell therapy is comprised of choroid plexus cells, which are naturally occurring ’support’ cells for the brain. LCT’s propriety technology IMMUPEL® coats the implanted cells to protect them from attack by the patient’s immune system.

The scientific basis for the Phase I clinical trial in humans was established from the published preclinical trial of NTCELL in a non-human primate model of Parkinson’s disease. The preclinical results indicate that NTCELL can protect and regenerate brain tissue that would otherwise be lost, potentially delaying or even preventing the effects of Parkinson’s disease.

“Unlike current therapy options for Parkinson’s disease, NTCELL may be neuroprotective and offers people living with the disease the hope of being able to halt disease progression and restore quality of life,” says Dr Grant.

LCT and Otsuka Pharmaceutical Factory (OPF) are co-developing NTCELL as a treatment for Parkinson’s disease. Under the agreement, LCT has already received a AU$3m cash payment and OPF is funding all of the research and development costs associated with the Phase I clinical trial, estimated at AU$2.1m. In addition, LCT will receive a second cash payment of AU$2m provided the DSMB authorise the remaining three implants later in the year.

ENDS

© Scoop Media